Abstract:Tau-targeting therapies for Alzheimer’s disease (AD) have received increasing attention in recent years, due to the clinical failure of various anti-amyloid β drugs and closer association between tau burden and cognitive impairments in AD patients. The intracellular tau aggregation is recognized as a vital event in tau pathway of AD progression. However, current developed tau aggregation inhibitors are still facing serious challenges on how to access the cytosol of cells where tau protein mainly located and differentiate pathological tau from normal tau. Herein, we report a customized biomimetic nanochaperone for targeting intracellular pathological tau, serving as a novel anti-tau therapy of AD. This nanochaperone was tailored by engineering VQIINK hexapeptide derived from tau protein onto the surface of self-assembly micelle equipped with chaperone-like hydrophobic microdomains and confined spaces. With the lysosomal microenvironment responsiveness of unique surface structure, the Tau-nChap can escape from lysosome and enter into cytoplasm to overcome the intracellular tau location challenge. More importantly, the cytosol-arrived nanochaperone can selectively capture pathological tau without interfering with normal tau and potently inhibit their aggregation through the synergic effect of tau-recognizing peptide and confined hydrophobic microdomain on surface. As a result, the tau-targeting nanochaperone rescues neuronal cells from tau-mediated neurotoxicity and ameliorates cognitive deficits of AD model mice. Therefore, we believe that this custom-built tau-nanochaperone represents a promising weapon for combating AD and provides valuable insights for the treatment of other neurodegenerative disorders induced by specific pathogenic proteins including Parkinson’s disease and Huntington’s disease.

Self-assembly Hollow Manganese Prussian White Nanocapsules Attenuate Tau-related Neuropathology and Cognitive Decline.

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer’s Disease Therapy

Hsp90 Co-Chaperone Degradation Combined with Antioxidation Nanostrategy to Rescue Tauopathy-Induced Alzheimer’s Disease

Intelligently Thermoresponsive Flower-Like Hollow Nano-Ruthenium System for Sustained Release of Nerve Growth Factor to Inhibit Hyperphosphorylation of Tau and Neuronal Damage for the Treatment of Alzheimer's Disease

Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy

A Novel Targeted and High‐Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease

Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease

Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer's Disease.

Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer's Disease

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer's Disease Therapy

Zn2+-responsive Palladium Nanoclusters Synergistically Manage Alzheimer’s Disease Through Neuroprotection and Inhibition of Oxidative Stress

Brain‐Penetrating and Disease Site‐Targeting Manganese Dioxide‐Polymer‐Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways

Functionalised penetrating peptide-chondroitin sulphate‑gold nanoparticles: Synthesis, characterization, and applications as an anti-Alzheimer's disease drug

Ultrasound-Excited Protoporphyrin IX-Modified Multifunctional Nanoparticles As a Strong Inhibitor of Tau Phosphorylation and Β-Amyloid Aggregation.

Zn 2+ -responsive palladium nanoclusters synergistically manage Alzheimer's disease through neuroprotection and inhibition of oxidative stress

“Cascaded Rocket” Nanosystems with Spatiotemporal Separation for Triple‐Synergistic Therapy of Alzheimer's Disease

Harnessing Nanochaperone-Mediated Autophagy for Selective Clearance of Pathogenic Tau Protein in Alzheimer's Disease

Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease.

Blood-brain barrier Permeable nanoparticles for Alzheimer's disease treatment by selective mitophagy of microglia

Dual-functional Nanoparticles for Precise Drug Delivery to Alzheimer’s Disease Lesions: Targeting Mechanisms, Pharmacodynamics and Safety